Expand PPCB Menu
PPCB MENU

PPCB Latest Press Releases

-- June 16, 2026 --

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study Globe Newswire 8:45 AM

-- June 11, 2026 --

ShareStructure.io Announces Investor Education Platform on Public Company Financing Activity. Globe Newswire 10:44 AM
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program Globe Newswire 8:30 AM

-- June 2, 2026 --

Propanc Biopharma's CEO Attends Keynote Address, "Rejuvenation and Health: Science for an Ageing Society," at the University of Granada, Spain Globe Newswire 5:30 AM

-- May 20, 2026 --

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade Globe Newswire 8:45 AM

-- May 19, 2026 --

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 - 40 Advanced Cancer Patients Globe Newswire 8:45 AM

-- May 15, 2026 --

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results Globe Newswire 8:45 AM

-- May 13, 2026 --

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans Globe Newswire 10:00 PM

-- April 16, 2026 --

Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation - PPCB Business Wire 10:48 AM

-- March 24, 2026 --

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jan and Granada, Spain Globe Newswire 8:45 AM

-- March 12, 2026 --

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy Globe Newswire 8:45 AM

-- March 10, 2026 --

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study Globe Newswire 8:45 AM

-- March 3, 2026 --

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models Globe Newswire 8:45 AM

-- February 18, 2026 --

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results Globe Newswire 8:45 AM

-- February 5, 2026 --

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market Globe Newswire 8:45 AM

-- January 27, 2026 --

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations Globe Newswire 8:45 AM

-- January 20, 2026 --

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes